D-0371-2022 Class II Terminated
FDA drug recall D-0371-2022 was initiated by Teva Pharmaceuticals USA on Dec 31, 2021 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Jun 4, 2024). Affected quantity: 11,450 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 19, 2022
- Initiation Date
- Dec 31, 2021
- Termination Date
- Jun 4, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 11,450 vials
Product description
Norepinephrine Bitartrate Injection USP 4 mg/4 mL (1 mg/mL), 4 mL Single-Dose Vials, 10 vials per carton, Rx Only, Manufactured By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, NDC 0703-1153-03.
Reason for recall
Lack of Assurance of Sterility
Distribution pattern
Methylprednisolone, TN Norepinephrine BItartrate - MS, OH
Code information
Lot # 100020800, exp 07/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0371-2022
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026